Altimmune, Inc.

NASDAQ:ALT

Biotechnology

Healthcare
$1.39 +3.09%

+$0.08 today

Market cap
$270.48M
Beta
0.23
P/E (TTM)
-3.7
EPS (TTM)
-$0.73
52W Low $2.56High $7.73

Volume 4.69M

Average 3.81M

ALT Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Altimmune, Inc.NASDAQ: ALT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $23K fell 20.7% year over year, ahead of the -33.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 11.5% from the prior quarter. Over 3 fiscal years it compounded at -39.0% a year.

Context

  • Depreciation & amortization amounted to 273.2% of revenue in FY2025, down 916.8 pp from a year earlier.
  • Depreciation & amortization increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.7% holds above the trailing-twelve-month pace of -33.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$23K-11.5% QoQ
Last fiscal yearDec 2025
$112K-52.9% YoY
LTMMar 2026
$106K-33.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.7%——
1 year-52.9%——
3-year CAGR-39.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
112K USD
Year-over-year change
-52.9%
4-year CAGR
-32.9%

Depreciation & Amortization vs competitors

How ALT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.8% is the 6th highest of 8, against a peer median of -6.2%.
  • Depreciation & amortization amounts to 294.4% of revenue for ALT, versus a peer median of 7.2%.
ALT Competitors
Depreciation & Amortization for ALT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VIRVir Biotechnology, Inc.LTM Mar 2026$18.23M USD+41.3%+46.1%27.8%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.95M USD+56.5%+19.6%7.2%
IVAInventiva S.A.FY2025€3.22M EUR-38.0%+23.8%71.9%
GPCRStructure Therapeutics Inc.LTM Jun 2026$2.47M USD+124.0%+68.8%—
ABUSArbutus Biopharma CorporationLTM Mar 2026$1.07M USD-21.3%-36.6%0.6%
BMEABiomea Fusion, Inc.LTM Mar 2026$960K USD-46.5%+26.8%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K USD-6.2%-36.3%0.2%
ALTAltimmune, Inc.LTM Mar 2026$106K USD-33.8%-39.0%294.4%
INDPIndaptus Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ALT) —-6.2%+23.8%7.2%

Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(97.09M)(84.71M)(88.45M)(95.06M)(88.09M)
Depreciation & Amortization551K493K477K238K112K
Deferred Income Tax0000(681K)
Stock-Based Compensation5.52M8.1M10.64M14.39M16.08M
Change in Working Capital(251K)14.11M(8.27M)4.48M6.75M
Accounts Receivables6.53M3.3M(2.31M)1.74M2.06M
Inventory00000
Accounts Payables1.42M2.77M(2.73M)(1.86M)2.51M
Other Working Capital(8.21M)8.04M(3.23M)4.6M2.19M
Other Non-Cash Items13.03M(578K)9.79M(3.9M)(1.7M)
Operating Cash Flow(78.24M)(62.59M)(75.81M)(79.85M)(67.54M)
Capital Expenditures(12.31M)(126K)(47K)0(11K)
Acquisitions (Net)00000
Purchases of Investments(7.59M)(73.27M)(88.63M)(115.73M)(285.45M)
Sales of Investments107.43M0102.41M87.35M152.99M
Other Investing Activities(195K)0000
Investing Cash Flow87.52M(73.4M)13.73M(28.39M)(132.47M)
Debt Repayment000033.92M
Common Stock Issued65.04M56.35M86.6M9.99M173.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities58K434K(496K)50K(709K)
Financing Cash Flow65.1M56.78M86.11M10.04M206.84M
Effect of Forex Changes00000
Net Change in Cash74.38M(79.2M)24.03M(98.19M)6.83M
Free Cash Flow(90.55M)(62.71M)(75.86M)(79.85M)(67.55M)

Altimmune, Inc.

NASDAQ:ALT

Intrinsic Alpha fair value

Locked

Current Price

$1.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.